Open Access
Twenty years of modelling NPM-ALK-induced lymphomagenesis
Sylvie Giuriato1,2,3,5,Suzanne D. Turner4,5,*
Inserm, UMR1037 CRCT, F-31000 Toulouse, France
Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000 Toulouse, France
CNRS, ERL5294 CRCT, F-31000 Toulouse, France
Division of Molecular Histopathology, Department of Pathology, Lab Block Level 3, Box 231, Addenbrooke’s Hospital, Cambridge CB20QQ
European Research Initiative on ALK-related malignancies (ERIA)
DOI: 10.2741/S437 Volume 7 Issue 2, pp.236-247
Published: 01 June 2015
(This article belongs to the Special Issue ALK: 20 years of discoveries)
*Corresponding Author(s):  
Suzanne D. Turner

Our current understanding of oncogenic Anaplastic Lymphoma Kinase (ALK)-induced lymphomagenesis has relied for over 20 years on multiple and complementary studies performed on various experimental models, encompassing ALK oncogene expressing cells, their grafts into immune-compromised mice, the generation of genetically engineered mouse models (GEMMs) and, when available, the use of patient samples from Anaplastic Large Cell Lymphoma (ALCL) tumour banks. Of note, and to our knowledge, no ALK-positive ALCL 3D culture system has been described so far. In this review, we will first outline how these different cell and mouse models were designed, and what key findings they revealed (or confirmed) towards oncogenic ALK-induced lymphomagenesis. Secondly, we will discuss how recent and revolutionary advances in genetic engineering technology are likely to complete our understanding of ALK-related diseases in an effort to improve current therapeutic approaches.

Key words

ALCL, NPM-ALK, Mouse models, Cancer models, In vitro cancer models, Review

Share and Cite
Sylvie Giuriato, Suzanne D. Turner. Twenty years of modelling NPM-ALK-induced lymphomagenesis. Frontiers in Bioscience-Scholar. 2015. 7(2); 236-247.